Optimization of an Experimental Vaccine To Prevent Escherichia

Optimization of an Experimental Vaccine To Prevent Escherichia coli Urinary Tract Infection

Design of the SARS-CoV-2 RBD vaccine antigen improves neutralizing antibody response

How Experimental Research Boosts Vaccine Efficacy

STAR-0215 is a Novel, Long-Acting Monoclonal Antibody Inhibitor of Plasma Kallikrein for the Potential Treatment of Hereditary Angioedema

In silico design of a promiscuous chimeric multi-epitope vaccine against Mycobacterium tuberculosis - Computational and Structural Biotechnology Journal

Modeling Framework for Vaccine Production - BioProcess InternationalBioProcess International

Frontiers The combination of vaccines and adjuvants to prevent the occurrence of high incidence of infectious diseases in bovine

Current view on novel vaccine technologies to combat human infectious diseases

Research implementation and evaluation of the maternity waiting home program for enhancing maternal health in remote area of Indonesia - Clinical Epidemiology and Global Health

E-COLI 0157 SRP - Vaxxinova

Optimized ACE2 decoys neutralize antibody-resistant SARS-CoV-2 variants through functional receptor mimicry and treat infection in vivo

Throughput-scalable manufacturing of SARS-CoV-2 mRNA lipid nanoparticle vaccines

Prioritizing vaccination by age and social activity to advance societal health benefits in Norway: a modelling study - The Lancet Regional Health – Europe

Vaccines, Free Full-Text